StockData
AN2 Therapeutics, Inc. logo

AN2 Therapeutics, Inc. (ANTX) stock

ANTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 8/30
$4.23−0.24 (-5.37%)

Close on Nov 17, 2026Market cap $159.62MP/E –Yield –

AN2 Therapeutics operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

AN2 Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$30.68M. For fiscal 2025 it was -$29.83M. The highest annual figure on record is -$20.48M in fiscal 2021.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$29.83M–
FY2024Dec 31, 2024-$49.26M–
FY2023Dec 31, 2023-$53.29M–
FY2022Dec 31, 2022-$33.46M–
FY2021Dec 31, 2021-$20.48M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$7.00M–
Q1 FY2026Mar 31, 2026-$12.07M–
Q4 FY2025Dec 31, 2025-$5.24M–
Q3 FY2025Sep 30, 2025-$6.38M–
Q2 FY2025Jun 30, 2025-$7.60M–
Q1 FY2025Mar 31, 2025-$10.62M–
Q4 FY2024Dec 31, 2024-$5.27M–
Q3 FY2024Sep 30, 2024-$12.01M–
Q2 FY2024Jun 30, 2024-$14.38M–
Q1 FY2024Mar 31, 2024-$17.59M–
Q4 FY2023Dec 31, 2023-$17.07M–
Q3 FY2023Sep 30, 2023-$11.80M–
Q2 FY2023Jun 30, 2023-$12.82M–
Q1 FY2023Mar 31, 2023-$11.60M–
Q4 FY2022Dec 31, 2022-$7.64M–
Q3 FY2022Sep 30, 2022-$9.49M–
Q2 FY2022Jun 30, 2022-$9.60M–
Q1 FY2022Mar 31, 2022-$6.74M–
Q4 FY2021Dec 31, 2021-$8.99M–
Q3 FY2021Sep 30, 2021-$4.69M–
Q2 FY2021Jun 30, 2021-$5.26M–
Q1 FY2021Mar 31, 2021-$1.54M–

More AN2 Therapeutics figures

See a number that looks wrong?